BD's board authorized the company to repurchase up to 10 million shares of its common stock in addition to those remaining under previous authorizations.
The medical technology company said Tuesday it repurchased $250 million in its stock to date in fiscal 2026.
The board previously authorized buyback programs in 2021 and 2025.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
January 27, 2026 17:26 ET (22:26 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments